The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

As a pediatric obesity medicine specialist, I have witnessed first-hand the benefits of GLP-1 receptor agonists in the ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking ...

Obesity is not a choice, it’s a chronic disease, says expert. The Treat and Reduce Obesity Act could have potential impact on ...